-
Protease Inhibitor Cocktail for OXPHOS Workflows
2026-09-02
Protect fragile signaling and mitochondrial proteins from extraction-related degradation with an EDTA-free, broad-spectrum formulation. This workflow connects controlled lysate preparation to Western blotting, Co-IP, kinase assays, and mechanistic OXPHOS studies involving LRPPRC inhibition and Dasatinib.
-
Ruxolitinib: Mechanism-First Immune Assay Design
2026-09-01
Ruxolitinib (INCB018424) is more than a JAK1/2 inhibitor: it is a practical tool for connecting pathway control with high-dimensional immune phenotyping. This guide translates its biochemical profile and recent murine sarcoma findings into better assay design, controls, and interpretation.
-
Rucaparib: A Causal Framework for DDR Assays
2026-09-01
Rucaparib (AG-014699) is a potent PARP1 inhibitor for dissecting DNA repair stress, radiosensitization, and cell-fate decisions. This article presents a causal assay framework that separates target engagement, persistent DNA breaks, transcriptional effects, and apoptosis.
-
Relative Versus Fractional Viability in Cancer Studies
2026-08-31
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. This framework improves interpretation of in vitro cancer pharmacology by incorporating response magnitude, composition, and timing rather than treating a single viability endpoint as a complete measure of cytotoxicity.
-
Metformin and Tendon Heterotopic Ossification
2026-08-31
A recent mouse Achilles tendon study identifies the Nr4a1/Wnt/β-catenin axis as a mechanistic link between Metformin HCl exposure and reduced heterotopic ossification. The work combines an in vivo tendon model, tendon-derived stem cell assays, transcriptomics, and pathway perturbation to show that metformin limits osteogenic differentiation rather than simply altering systemic glucose control.
-
Balsalazide: Evidence for Colon-Targeted 5-ASA
2026-08-30
The 2009 review by Wiggins and Rajapakse evaluated balsalazide as a colon-activated 5-aminosalicylic acid prodrug for mild-to-moderate active ulcerative colitis. Its central contribution was to connect azo-bond design, bacterial activation, clinical remission data, and comparative tolerability, while highlighting faster remission induction than mesalamine in the available evidence.
-
PMSF for Protease-Controlled Immune Assays
2026-08-29
PMSF is more than a routine extraction additive: it is a pre-analytical control for proteolysis in temporal immune and extracellular-vesicle assays. This article explains how its selective chemistry can strengthen interpretation of shrimp hemocyte epigenetic studies while clarifying important limitations.
-
20-HETE–TRPV1 Signaling in Chronic Dermatitis
2026-08-28
The reference study identifies elevated 20-HETE as a lipid mediator that activates sensitized TRPV1 channels on MrgprA3+ sensory neurons, helping explain why normally painful stimuli can provoke itch in chronic dermatitis. By combining behavioral, electrophysiological, chemogenetic, metabolomic, and pharmacological approaches, the work links lesional-skin metabolism to pathological sensory switching and highlights 20-HETE synthesis as a potential intervention point.
-
Okadaic acid: PP1/PP2A Workflow Guide
2026-08-28
Okadaic acid (A4540) provides a controlled way to inhibit serine/threonine phosphatases PP2A and PP1 when phosphorylation-dependent signaling or apoptosis-related endpoints must be interrogated. It is suitable for biochemical and cell-based studies with matched vehicle controls, but it should not be treated as a broad phosphatase inhibitor or as evidence that a downstream phenotype is specific to one pathway.
-
Humanized Mice Clarify HD56 Prodrug Pharmacokinetics
2026-08-27
A 2025 Drug Metabolism and Disposition study shows that humanized-liver mice can resolve species-dependent metabolism of the carboxylesterase-activated prodrug HD56 more effectively than conventional preclinical species. Its strong in vivo–in vitro correlation supports humanized models as a practical tool for improving pharmacokinetic prediction during ester-prodrug development.
-
Pentoxifylline and LPS Inflammation in Preterm Monocytes
2026-08-27
Schüller and colleagues examined how pentoxifylline reshapes LPS-triggered monocyte responses across preterm infants, term infants, and adults. The study links reduced inflammatory cytokines and surface activation markers to suppression of TLR4 expression and signaling, while also identifying age-dependent effects that are important for neonatal sepsis research.
-
HyperFusion high-fidelity DNA polymerase Workflow
2026-08-26
Build more reliable C. elegans neurodegeneration assays with a proofreading DNA polymerase designed for accurate, rapid amplification of long, GC-rich, or inhibitor-laden templates. HyperFusion™ combines high fidelity, blunt-end products, and a streamlined reaction format for cloning, genotyping, and sequencing-oriented workflows.
-
HyperFusion™ high-fidelity DNA polymerase Guide
2026-08-26
A scenario-driven guide to using HyperFusion™ high-fidelity DNA polymerase (SKU K1032) for molecular validation in cell viability, proliferation, and cytotoxicity workflows. It explains how proofreading fidelity, inhibitor tolerance, and simple reaction setup can support more dependable PCR-based genotyping, cloning, and sequencing decisions.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-08-25
MDL 28170 combines nanomolar calpain inhibition with cell permeability and brain exposure, making it useful for mechanistic neuroprotection research as well as selected cardiac and infectious-disease models. This guide translates the compound’s properties and recent BDNF/TrkB findings into practical workflows, controls, and troubleshooting decisions.
-
Crystal Violet in C. auris Translational Research
2026-08-25
A translational framework for using Crystal Violet Staining Solution as a rigorous imaging endpoint while interpreting Candidozyma auris phenotypes alongside genomic, antifungal susceptibility, virulence, and biofilm data.